



Tenofovir Alone as PrEP May Fail

January 19, 2016

Two cases have been documented of gay men taking Viread (tenofovir), one of the two drugs in Truvada (tenofovir/emtricitabine), for hepatitis B virus (HBV) and contracting HIV, aidsmap reports. These cases suggest that Viread alone may not be enough to prevent HIV through pre-exposure prophylaxis (PrEP), and that Emtriva (emtricitabine) is also required for such prevention. However, there is a possibility that the presence of hep B may have increased the men's risk of HIV acquisition.

Publishing their analysis in *Infectious Diseases and Therapy*, researchers documented case reports of two gay men who contracted HIV while adhering to a Viread regimen to treat hep B.

In one of the men, the Viread wound up suppressing his new HIV infection to undetectable levels. The other man had a viral load of about 100,000 shortly after contracting HIV, a moderate level for an acute infection. Tests indicated that HIV had sufficiently integrated into the cells of each man to establish a permanent infection.

To read the aidsmap article, [click here](#).

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.poz.com/article/PrEP-HBV-28298-5625>